Page 52 - JCTR-10-5

314 Arnold and Arm | Journal of Clinical and Translational Research 2024;10(5):307-316
saturation with NIR imaging in the VLU case presented here formal research protocol were required, nor were the cases added
supports the use of PMVT and addresses a key risk factor for to a public database. All facility procedures for obtaining patient
non-healing. The restoration of the microcirculation enables consent for treatment were followed, and release forms to allow
increased oxygen and nutrient delivery to the wound, which data and image publication were obtained from each patient.
promotes granulation and wound epithelialization [40].
This case series demonstrates the breadth of potential Consent for Publication
applications for PMVT in real-world clinical experience, beyond As this case series was conducted under standard practice
the previously published Level 1 RCT data neuropathic DFUs. of medicine with a commercial human tissue product for each
Podiatrists, plastic and reconstructive surgeons, and wound care respective application, no additional ethical regulations or
practitioners may all benefit from learning about the outcomes formal research protocol were required, nor were the cases
in this series for their own hard-to-heal wounds and skin defects added to a public database. All facility procedures for obtaining
in patients with damaged or deficient microvasculature. The patient consent for treatment were followed, and release forms
authors recognize that the number of patients treated within to allow data and image publication were obtained from each
each wound category reported here is limited, and that ideally a patient.
more formal protocol-driven case series or clinical trial would
provide additional insight into PMVT’s effectiveness in these Availability of Data
different types of wounds. PMVT is limited to local applications Due to commercial reasons, access to the data that support
only; intravascular or other systemic delivery is contraindicated.
the findings of this case series is restricted.
5. Conclusion
References
While the broad conclusions that can be drawn from this
series of challenging wound cases are limited, it is evident that [1] Gosain A, DiPietro LA. Aging and Wound Healing.
World J Surg 2004;28:321-6.
the use of PMVT can benefit patients with non-healing or at-
risk tissue defects of different types caused by microvascular doi: 10.1007/s00268-003-7397-6
insufficiencies. All defects fully healed in the five cases [2] Guo S, DiPietro LA. Factors Affecting Wound Healing.
presented in this series, with patients requiring 3 – 8 topical J Dent Res 2010;89:219-29.
PMVT applications before closure. Tissue in the healing defect doi: 10.1177/0022034509359125
sites became progressively more granulated during PMVT [3] Mathieu D, Linke JC, Wattel F. Non-Healing Wounds. In:
treatment, as assessed through visual observation and NIR Mathieu DE, editor. Handbook on Hyperbaric Medicine.
spectroscopy images of tissue oxygenation. This is indicative Ch. 2.2.9. Amsterdam: Springer; 2006. p. 401-27.
of PMVT’s ability to support the repair and reconstruction of [4] Menke NB, Ward KR, Witten TM, Bonchev DG,
microvascular tissue, which, in turn, drove complete wound Diegelmann RF. Impaired Wound Healing. Clin
healing. Successful closure of these refractory and challenging Dermatol 2007;25:19-25.
cases across the spectrum of non-healing and at-risk wounds doi: 10.1016/j.clindermatol.2006.12.005
demonstrates both the broad importance of repairing and
reconstructing damaged or deficient microvascular tissue and [5] Shaw TJ, Martin P. Wound Repair at a Glance. J Cell Sci
the use of PMVT to improve healing in multiple complex 2009;122(18):3209-13.
wound environments. doi: 10.1242/jcs.031187
[6] Dulmovits BM, Herman IM. Microvascular Remodeling
Acknowledgments and Wound Healing: A Role for Pericytes. Int J Biochem
The PMVT product used in this case series was provided by Cell Biol 2012;44:1800-12.
MicroVascular Tissues, Inc. doi: 10.1016/j.biocel.2012.06.031
[7] Pham HT, Economides PA, Veves A. The Role of
Funding Endothelial Function on the Foot. Microcirculation and

None. Wound Healing in Patients with Diabetes. Clin Podiatr
Med Surg 1998;15:85-93.
Conflict of Interest [8] Yuan SY, Rigor RR. Structure and Function of Exchange
J.F.A. reports no conflict of interest. D.M.A. is an employee Microvessels. In: Regulation of Endothelial Barrier
of MicroVascular Tissues, Inc., the company that provided the Function. Ch. 2. San Rafael, CA: Morgan and Claypool
product for this case series. Life Sciences; 2010.
[9] Kim Y, Ko H, Kwon IK, Shin K. Extracellular Matrix
Ethics Approval and Consent to Participate Revisited: Roles in Tissue Engineering. Int Neurourol J
As this case series was conducted under standard practice 2016;20:S23-9.
of medicine with a commercial human tissue product for each doi: 10.5213/inj.1632600.318
respective application, no additional ethical regulations or [10] Xu J, Shi GP. Vascular Wall Extracellular Matrix

DOI: http://doi.org/10.36922/jctr.24.00059